Laboratorio De Bioquímica Y Biología Molecular, Centro De Química Del Instituto De Ciencias (ICUAP), Ciudad Universitaria, Benemérita Universidad Autónoma De Puebla, Puebla, México.
Dirección De Innovación Y Transferencia De Conocimiento, Benemérita Universidad Autónoma De Puebla, Puebla, México.
Expert Opin Ther Pat. 2020 May;30(5):307-311. doi: 10.1080/13543776.2020.1732352. Epub 2020 Feb 27.
: GITR is a receptor that increases the activation of T lymphocytes against tumor cells. There is a great need to discover and develop new therapies focused on activating GITR to increase the immune response in various types of cancer. The authors of WO2018091739 patent propose a method to eradicate cancer by using bispecific anti-GITR/anti-CTLA-4 antibodies.: WO2018091739 patent describes anti-GITR/anti-CTLA-4 antibodies, pharmaceutical composition that contains it, and their application for cancer treatment, particularly colon carcinoma. Anti-GITR/anti-CTLA-4 antibodies are used at a dosage of 0.0003-3 mg antibody/kg patient weight and is suspended in an isotonic solution consisting of sodium phosphate, sucrose, NaCl, and polysorbate 80.: WO2018091739 only demonstrates that bispecific antibodies activate T cells, an antibody-dependent cellular cytotoxicity of CHO cells, and tumor inhibition in murine models of colon carcinoma. There are no clinical trials that show that treatment with bispecific antibodies can induce an antitumor response in cancer patients.
GITR 是一种受体，可增强针对肿瘤细胞的 T 淋巴细胞的激活。非常需要发现和开发新的疗法，专注于激活 GITR 以增加各种类型癌症的免疫反应。WO2018091739 专利的作者提出了一种通过使用双特异性抗 GITR/抗 CTLA-4 抗体来消灭癌症的方法。
WO2018091739 专利描述了抗 GITR/抗 CTLA-4 抗体、包含它的药物组合物及其在癌症治疗中的应用，特别是结肠癌。抗 GITR/抗 CTLA-4 抗体的剂量为 0.0003-3mg 抗体/kg 患者体重，并悬浮在由磷酸钠、蔗糖、NaCl 和聚山梨醇 80 组成的等渗溶液中。
WO2018091739 仅表明双特异性抗体可激活 T 细胞、CHO 细胞的抗体依赖性细胞细胞毒性以及结肠癌的鼠模型中的肿瘤抑制作用。没有临床试验表明用双特异性抗体治疗可以诱导癌症患者的抗肿瘤反应。
